AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 283: E367-E373, 2002. First published February 5, 2002; doi:10.1152/ajpendo.00185.2001
0193-1849/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/2/E367    most recent
00185.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Severino, C.
Right arrow Articles by Tonolo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Severino, C.
Right arrow Articles by Tonolo, G.
Vol. 283, Issue 2, E367-E373, August 2002

Low-dose dexamethasone in the rat: a model to study insulin resistance

C. Severino1,2, P. Brizzi1, A. Solinas2, G. Secchi1, M. Maioli1, and G. Tonolo1

1 Servizio Diabetologia, Dipartimento Struttura Clinica Medica e Patologia Speciale Medica, and 2 Dipartimento Scienze Biomediche Sezione di Fisiologia Umana, Universita' di Sassari, 07100 Sassari, Italy

The main aim of this study was to set up a new animal model to study insulin resistance. Wistar rats (6 or 7 per group) received the following for 4 wk in experiment 1: 1) vehicle, 2) 2 µg/day subcutaneous dexamethasone, 3) metformin (400 mg · kg-1 · day-1 os), and 4) dexamethasone plus metformin. In experiment 2 the rats received the following: 1) vehicle, 2) dexamethasone, 3) dexamethasone plus arginine (2%; as substrate of the nitric oxide synthase for nitric oxide production) in tap water, and 4) dexamethasone plus isosorbide dinitrate (70 mg/kg; as direct nitric oxide donor) in tap water. Insulin sensitivity was significantly reduced by dexamethasone already at week 1, before the increase in blood pressure (day 15) and without significant changes in body weight compared with vehicle. Dexamethasone-treated rats had significantly higher triglycerides, hematocrit, and insulin, whereas serum total nitrates/ nitrites were lower compared with vehicle. The concomitant treatment with metformin minimized all the described effects of dexamethasone. In experiment 2, only isosorbide dinitrate was able to prevent the observed dexamethasone-induced metabolic, hemodynamic, and insulin sensitivity changes. Chronic low-dose subcutaneous dexamethasone (2 µg/day) is a useful model to study the relationships between insulin resistance and blood pressure in the rat, and dexamethasone might decrease insulin sensitivity and increase blood pressure through an endothelium-mediated mechanism.

glucocorticoids; metabolic syndrome; metformin; hypertension


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Puthanveetil, F. Wang, G. Kewalramani, M. S. Kim, E. Hosseini-Beheshti, N. Ng, W. Lau, T. Pulinilkunnil, M. Allard, A. Abrahani, et al.
Cardiac glycogen accumulation after dexamethasone is regulated by AMPK
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1753 - H1762.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Kewalramani, P. Puthanveetil, M. S. Kim, F. Wang, V. Lee, N. Hau, E. Beheshti, N. Ng, A. Abrahani, and B. Rodrigues
Acute dexamethasone-induced increase in cardiac lipoprotein lipase requires activation of both Akt and stress kinases
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E137 - E147.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. L. Thunhorst, T. G. Beltz, and A. K. Johnson
Glucocorticoids increase salt appetite by promoting water and sodium excretion
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1444 - R1451.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Le Foll, C. Corporeau, V. Le Guen, J.-P. Gouygou, J.-P. Berge, and J. Delarue
Long-chain n-3 polyunsaturated fatty acids dissociate phosphorylation of Akt from phosphatidylinositol 3'-kinase activity in rats
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1223 - E1230.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Qi and B. Rodrigues
Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E654 - E667.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. J. Holness, G. K. Greenwood, N. D. Smith, and M. C. Sugden
Peroxisome Proliferator-Activated Receptor-{alpha} and Glucocorticoids Interactively Regulate Insulin Secretion During Pregnancy
Diabetes, December 1, 2006; 55(12): 3501 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Qi, D. An, G. Kewalramani, Y. Qi, T. Pulinilkunnil, A. Abrahani, U. Al-Atar, S. Ghosh, R. B. Wambolt, M. F. Allard, et al.
Altered cardiac fatty acid composition and utilization following dexamethasone-induced insulin resistance
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E420 - E427.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Korach-Andre, J. Gao, J. S. Gounarides, R. Deacon, A. Islam, and D. Laurent
Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E106 - E116.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online